Origent’s Chief Science Officer Dr. David Ennist will join several other ALS community leaders as a panelist at the ALS Community Workshop with the theme Developing Drugs for Treatment; Guidance for Industry.
This ALSA-led event, which will occur on July 12, 2018 seeks provide targeted feedback and information to the Food and Drug Administration (FDA) from people with ALS, caregivers, and stakeholders to inform revisions of the FDA’s Draft Guidance on ALS Drug Development. Panelists will include persons living with ALS, as well as representatives from Origent, Cytokinetics, Voyager Therapeutics, Biogen, Massachusetts General Hospital, Columbia University, The University of Iowa, Barrow Neurological Institute, Carolinas Healthcare System, Johns Hopkins University, and Mayo Clinic.
The conference is scheduled to occur from 9:00 AM – 3:00 PM Eastern U.S. time on July 12, 2018, and will be webcast. Register at the ALSA website to join the event via webcast.